Does systemic thrombolytic therapy reduce mortality and PE recurrence in patients with acute PE?
Patients with acute pulmonary embolism (PE), including haemodynamically stable patients
Systemic thrombolytic therapy
Total mortalityhard clinical
Systemic thrombolysis improves mortality and reduces recurrence in acute PE but at the cost of increased major and intracranial hemorrhage, with no significant mortality benefit in hemodynamically stable patients.
Thrombolytic therapy reduces total mortality, PE recurrence, and PE-related mortality in patients with acute PE. The decrease in overall mortality is, however, not significant in haemodynamically stable patients with acute PE. Thrombolytic therapy is associated with an increase of major and fatal or intracranial haemorrhage.
Building similarity graph...
Analyzing shared references across papers
Loading...
Christophe Marti
Gregor John
Stavros Konstantinides
European Heart Journal
Inserm
Université Paris Cité
Assistance Publique – Hôpitaux de Paris
Building similarity graph...
Analyzing shared references across papers
Loading...
Marti et al. (Tue,) studied this question.
www.synapsesocial.com/papers/69dae32b387cf70698687e9e — DOI: https://doi.org/10.1093/eurheartj/ehu218